- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05398380
Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research
Clinical Impact of Molecular Biomarkers in Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective multicenter Spanish clinical phase II trial is proposed. The study population will consist of male and female with non-resectable CRLM, who are 18 to 70 years old, inclusive, at the time of providing informed consent. Patients will be identified, treated and followed by the clinical investigators within the different centers included in the present study. Those patients deemed unresectable CRLM by consensus in multidisciplinary meeting will be pre-screened for eligibility to be included in the study. After receiving the corresponding chemotherapy and if the patient meets the inclusion criteria and none of the exclusion criteria will sign the informed consent and will be evaluated for liver transplantation according to institutional protocols at the transplant unit. Patients eligible for liver transplantation will continue chemotherapy until the time of an organ is available. However, patients receiving treatment with bevacizumab or aflibercept will discontinue this treatment at time of inclusion in waiting list. If there are no further contraindications at the time of transplantation, laparotomy including tumor staging will be performed and if there is no sign of extrahepatic disease, liver transplantation will continue according to institutional protocols. Participants will be followed for 5 years and monitored for safety, survival and disease recurrence.
Regarding the translational research:
- The metastatic liver removed on day of transplant will be analysed using high-throughput single-cell RNA sequencing (scRNA-seq) which will allow deep phenotyping of cells for detection of rare and common cell populations and determination of developmental trajectories of distinct cell lineages.
- RAS allele fraction will be monitored by BEAMing and it will be performed before chemotherapy treatment, before LT, post-transplantation, and every 3 months until the patient relapses if relapses.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: CRISTINA DOPAZO, MD/PhD
- Phone Number: +34932746113
- Email: cristina.dopazo@vallhebron.cat
Study Contact Backup
- Name: CRISTINA DOPAZO
- Phone Number: +34932746113
- Email: cristina.dopazo@vallhebron.cat
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Department of HPB Surgery and Transplants, Hospital Vall d´Hebron
-
Contact:
- Cristina Dopazo, PhD/MD
- Phone Number: 6113 +34932746000
- Email: cristina.dopazo@vallhebron.cat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to provide written informed consent.
- Male or female, aged 18-70 years old inclusive at study entry.
- ECOG (Eastern Cooperative Oncology Group) 0 or 1.
- Histologically-proven primary colorectal tumor.
- Bilateral, limited at liver and non-resectable CRLM by consensus in Multidisciplinary Committee.
- Resection of primary colorectal tumor according oncological principles and adequate TNM stage.
- Time from primary colorectal tumor resection to transplant ≥ 12 months.
- Primary colorectal tumor stage ≤ T3N1. If time between primary tumor resection is ≥ 2 years, stage T4N0 or T4N2 is accepted.
- No signs of extrahepatic metastatic disease according to PET/CT scan, CT and pelvic MRI.
- The patient has undergone systemic chemotherapy for a minimum of 3 months at the time of screening and maximum of 2 lines of fluoropyrimidine based chemotherapy combined or not with irinotecan or oxaliplatin associated or no not with targeted therapy based in molecular biomarkers.
- Demonstrated stability or partial regression of CRLM following RECIST criteria v 1.1., at minimum 3 months since the last treatment received and immediately prior to screening.
- CEA (Carcinoembryonic antigen) values ≤ 80 µg/L immediately prior to screening.
Adequate blood test regarding:
- Creatinine ≤1.25 x upper normal level or estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73m2 using following the Chronic Kidney disease epidemiology collaboration (CKD-EPI) formula.
- Platelets ≥80 × 109/L
- Neutrophiles ≥ 2.5 × 109/L
- Patients with hepatic failure after resection will be considered if it occurs as a consequence of an inadequate preoperative estimation of the functional volume that would have contraindicated the surgery. They should meet the inclusion criteria and none of the exclusion criteria.
Exclusion Criteria:
- Largest Lesion >5.5cm immediately prior to screening
- Patients with Lynch Syndrome
- BRAF mutation and/or primary tumor of microsatellite instability (MSI)
- Recurrence of primary tumor confirmed by colonoscopy or pelvic MRI within the last 12 months prior to screening.
- Previous or concurrent cancer in the last 5 years. Any cancer curatively treated 5 years prior to entry or treated basal cell carcinoma is permitted.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient´s participation in the study or evaluation of the study results.
- Cardiac or pulmonary disease uncontrolled as contraindication for any surgical procedure.
- Active infection.
- Pregnant or breast-feeding patients
- Any reason why in the opinion of the investigator, the patient should not participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transplantation
Liver transplantation for the treatment of unresectable colorectal cancer liver metastases
|
Liver transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Five years overall survival
Time Frame: 5 years
|
Percentage of subject who reach the endpoint of overall survival from the inclusion in waiting list until death or last follow-up
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
One and three years overall survival
Time Frame: 1 and 3 years
|
Percentage of subjects who reach the endpoint of overall survival from the inclusion in waiting list until death or last follow-up
|
1 and 3 years
|
One, three and five years recurrence free survival
Time Frame: 1, 3 and 5 years
|
Percentage or patients who did not progress from transplantation until death or last follow-up analysed using Kaplan-Meier and the log-rank test.
|
1, 3 and 5 years
|
Number of patients that drop-out of the study prior to receive intervention
Time Frame: Prior to liver transplantation
|
Percentage of patients that drop-out of the study prior to liver transplantation
|
Prior to liver transplantation
|
Patterns of cancer recurrence after liver transplantation
Time Frame: 5 years
|
Defined as porcentage of patients with hepatic recurrence, extrahepatic recurrence or both
|
5 years
|
Changes in quality of life assessed by EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30)
Time Frame: 5 years
|
These questions allowed categorizing patients into whether they exhibited a clinically important symptom/functional impairment for each scale from 1 (not at all) to 4 (very much).
It would be assessed pretransplantation and every 6 months after transplantation.
|
5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of the intratumoral genetic heterogeneity of the metastatic liver through an in-depth lineage study
Time Frame: On day of transplantation
|
High-throughput single-cell RNA sequencing (scRNA-seq) will allow deep phenotyping of cells, allowing detection of rare and common cell populations and determination of developmental trajectories of distinct cell lineages from the metastatic liver removed to the recurrence (hepatic or extrahepatic).
|
On day of transplantation
|
Percentage of patients with circulating tumor DNA (ctDNA)
Time Frame: 5 years
|
ctDNA monitorization will be performed pre-chemotherapy, pre-transplantation and every three months after transplantation
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ramón Charco, Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron
- Principal Investigator: Elena Elez, Department of Oncology, Hospital Universitario Vall d´Hebron
- Principal Investigator: Cristina Dopazo, Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron
- Study Chair: Ernest Hidalgo, Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron
- Study Chair: Itxarone Bilbao, Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron
- Study Chair: Concepción Gómez-Gavara, Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron
- Study Chair: Mireia Caralt, Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron
- Study Chair: Javier Ros, Department of Oncology, Hospital Universitario Vall d´Hebron
- Study Chair: Francesc Salva, Department of Oncology, Hospital Universitario Vall d´Hebron
- Study Chair: Isabel Campos-Varela, Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d´Hebron
- Study Chair: Lluis Castells, Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d´Hebron
Publications and helpful links
General Publications
- Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjot L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. Erratum In: JAMA Oncol. 2019 Jun 13;:
- Dueland S, Grut H, Syversveen T, Hagness M, Line PD. Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant. 2020 Feb;20(2):530-537. doi: 10.1111/ajt.15682. Epub 2019 Nov 28.
- Elez E, Chianese C, Sanz-Garcia E, Martinelli E, Noguerido A, Mancuso FM, Caratu G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argiles G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.
- Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946. doi: 10.1016/S2468-1253(21)00219-3. Epub 2021 Sep 8. Erratum In: Lancet Gastroenterol Hepatol. 2021 Nov;6(11):e7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- METLIVER Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Liver transplantation
-
University of ZurichUnknownDeath | ComplicationSwitzerland
-
Austral University, ArgentinaCompleted
-
Rutgers, The State University of New JerseyRecruitingIntrahepatic Cholangiocarcinoma | Cholangiocarcinoma, IntrahepaticUnited States
-
Oslo University HospitalRecruiting
-
University Health Network, TorontoCompleted
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedLiver Cancer | Hepatobiliary Tract Adenomas and CarcinomasUnited States
-
Republican Specialized Scientific and Practical...RecruitingLiver Cirrhosis | Liver Transplant; ComplicationsUzbekistan
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
University of LiegeUniversitaire Ziekenhuizen KU Leuven; University Hospital, Ghent; University... and other collaboratorsRecruitingHepatocellular CarcinomaBelgium
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingLiver Diseases | Liver Transplantation | Liver Neoplasms | Gastrointestinal Stromal Tumors | Metastasis | Liver Metastases | Liver Transplant; Complications | Liver Cancer | Liver Transplant Disorder | Liver Carcinoma | GIST, Malignant | GIST | Metastases | Metastatic Liver Cancer | Gastrointestinal Stromal Tumor of... and other conditionsSpain